Rallybio Corp (NASDAQ: RLYB) closed the day trading at $1.80 down -1.64% from the previous closing price of $1.83. On the day, 739102 shares were traded.
Ratios:
For a better understanding of RLYB, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.39 and its Current Ratio is at 12.39. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on February 07, 2024, Downgraded its rating to Hold and sets its target price to $1.50 from $7 previously.
On April 17, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $18.
On April 10, 2023, Wedbush started tracking the stock assigning a Outperform rating and target price of $17.Wedbush initiated its Outperform rating on April 10, 2023, with a $17 target price.
Stock Price History:
Over the past 52 weeks, RLYB has reached a high of $9.14, while it has fallen to a 52-week low of $1.23.
Shares Statistics:
A total of 37.83M shares are outstanding, with a floating share count of 17.24M. Insiders hold about 54.41% of the company’s shares, while institutions hold 35.79% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of -$0.46 for the current quarter, with a high estimate of -$0.36 and a low estimate of -$0.53, while EPS last year was -$0.43. The consensus estimate for the next quarter is -$0.4, with high estimates of -$0.27 and low estimates of -$0.58.
Analysts are recommending an EPS of between -$1.06 and -$2.11 for the fiscal current year, implying an average EPS of -$1.55. EPS for the following year is -$1.44, with 7 analysts recommending between -$0.81 and -$2.09.
